Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society（2023）
摘要
Our pharmacovigilance study suggested increased reporting of interstitial lung disease related to PARPi particularly olaparib.
更多查看译文
关键词
interstitial lung disease,polymerase inhibitors,clinical trials,adp-ribose
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要